Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors (Q36872284)

16 August 2017

1 reference

title

Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors (English)

1 reference

16 August 2017

Jade Homsi

1

1 reference

PubMed ID

17615535

16 August 2017

Adil I Daud

series ordinal

2

1 reference

16 August 2017

1 July 2007

1 reference

16 August 2017

1 reference

16 August 2017

14

1 reference

16 August 2017

3

1 reference

16 August 2017

285-294

1 reference

Isolation of a tumor factor responsible for angiogenesis

16 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Inhibition of tumor angiogenesis mediated by cartilage

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

The biology of vascular endothelial growth factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Vascular growth factors and lymphangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Tie receptors: new modulators of angiogenic and lymphangiogenic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Redefining the target: chemotherapeutics as antiangiogenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

The role of VEGF receptors in angiogenesis; complex partnerships

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Receptor signaling: when dimerization is not enough

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Identification of placenta growth factor determinants for binding and activation of Flt-1 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

The PDGF family: four gene products form five dimeric isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Chromosomal location, exon structure, and vascular expression patterns of the human PDGFC and PDGFD genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Roles of PDGF in animal development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

PDGF signaling in cells and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Platelet-Derived Growth Factor is AngiogenicIn Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Renal-cell carcinoma--molecular pathways and therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Leflunomide in the treatment of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

Vascular Endothelial Growth Factor Induction of the Angiogenic Phenotype Requires Ras Activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480701400312

10.1177/107327480701400312

21 January 2018

Identifiers

DOI

0 references

PubMed ID

17615535

1 reference

PubMed ID

17615535